Credo Technology Group Holding Ltd vs Koninklijke Philips NV — how do they compare? Credo Technology Group Holding Ltd trades at $217.09 (market cap $39.82B), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.17% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Koninklijke Philips NV for 84 Days on average.
| CRDO | PHG | |
|---|---|---|
Market Cap | $39.82B | $23.52B |
Volume | 9,451,558 | 1,635,069 |
Sector | Technology | Health |
52-Week High | $302.52 | $32.91 |
52-Week Low | $87.81 | $23.81 |
Typical Hold Time | 22 Days | 84 Days |
Enterprise Value | $39.08B | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum showing bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth and 33.83% net income margins, though valuation metrics remain elevated with a P/E of 74.6. Recent earnings beats and analyst optimism highlight CRDO's position in AI infrastructure connectivity.
Outlook remains positive given triple-digit revenue growth and expanding AI data center demand, but premium valuation and insider selling present near-term risks. Wall Street consensus targets $267.33 with 87.5% buy ratings, though execution risks and customer concentration require monitoring amid rapid expansion.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →